A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7637 participants.

Also called NCT01959529

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,637 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01959529
  • EudraCT 2013-002371-17
Other papers using this trial's data
  • Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) Diabetes, obesity & metabolism, 2019-07 DOI, PubMed 30850995, PMC6617815 In the PMC Open Access subset under CC BY-NC.
  • DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality Diabetologia, 2018-01 DOI, PubMed 28913543, PMC6002964 In the PMC Open Access subset under CC BY.
  • Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) Diabetologia, 2018-01 DOI, PubMed 28913575, PMC6002963 In the PMC Open Access subset under CC BY.
  • Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1 American heart journal, 2016-09 DOI, PubMed 27595693
  • Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) Therapeutic innovation & regulatory science, 2019-03 DOI, PubMed 29793353
  • Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes The New England journal of medicine, 2017-08-24 DOI, PubMed 28605603, PMC5731244 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14 Cardiovascular diabetology, 2019-11-15 DOI, PubMed 31729990, PMC6858747 In the PMC Open Access subset under CC BY.
  • Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE BMJ open diabetes research & care, 2021-11 DOI, PubMed 34819298, PMC8614152 In the PMC Open Access subset under CC BY-NC.
  • Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10) Diabetes, obesity & metabolism, 2019-06 DOI, PubMed 30793465, PMC6504564 In the PMC Open Access subset under CC BY-NC.
  • Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) Diabetes & vascular disease research, 2020 DOI, PubMed 33280425, PMC7919227 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Argentina, Brazil, Canada, Croatia, Greece, India, Italy, Japan, Malaysia, Mexico, Poland, Romania, Russia, South Africa, South Korea, Spain, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01959529. Randomized; double masking; primary purpose treatment. Start 2013-10-29 (actual); primary completion 2016-10-16 (actual). Results posted on 2017-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Acronym
DEVOTE
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01959529
Content hash
76b90c09baf5042295b7dd4803e4c5fef8832720f413731e19c05886be5525d2